Beyond Air Reports 107% Annual Revenue Surge to $7.7M, Guides $16–18M in 2027
XAIR•Beyond Air posted 107% revenue growth to $7.7 million for fiscal 2026 and 66% revenue growth to $1.9 million in Q4. The company guides $8 million revenue for calendar 2026 and forecasts $16–18 million or more than 110% growth for 2027.
1. Fiscal 2026 Financial Results
Beyond Air’s full fiscal year 2026 revenue climbed 107% to $7.7 million, driven by increased demand for LungFit PH domestically and internationally. The fiscal fourth quarter saw revenue rise 66% to $1.9 million, gross profit improve to $94,000 and net loss widen to $10.3 million or $0.77 per share.
2. Calendar 2026-27 Guidance
The company shifted its year-end to December 31 and issued revenue guidance of $8 million for calendar 2026, reflecting approximately 15% growth. It also projected $16–18 million for calendar 2027, representing more than 110% growth, based on expanding commercial traction.
3. Leadership and Corporate Actions
Robert Goodman assumed the CEO role in March 2026 and Dan Moorhead joined as CFO in January 2026, strengthening executive leadership. The board approved a 1-for-20 reverse stock split to regain Nasdaq compliance by July 31, 2026.
4. Regulatory Milestones
Beyond Air’s PMA supplement for its second-generation LungFit PH system remains under FDA review, aiming to expand labeling for patient transport. Approval could quadruple the U.S. addressable market to $400 million and raise the global opportunity above $1 billion.
